|
Items |
Warfarin |
Superwarfarin |
|
Substance |
Warfarin |
Brodifacoum [1]、bromadiolone[1]、difenacoum[2]、difethialone [2] |
|
agent |
Anti-coagulant |
Rodenticide |
|
Action site |
VKORC1(Vitamin K epoxide reductase complex
subunit 1 [3] |
VKORC1 |
|
Mechanism [3] |
(reduced vitamin K) to function
as a cofactor for enzymes. Warfarin blocks this reduction
process, leading to the depletion of active vitamin K in the body. |
(reduced vitamin K) to function as a
cofactor for enzymes. Warfarin blocks this reduction
process, leading to the depletion of active vitamin K in the body. |
|
Affected factors [4] |
II、VII、IX、X;Protein C/S |
II、VII、IX、X;Protein C/S |
|
Effectiveness after |
INR prolonged for 2- 6 hours to
1.5 days [5] |
Typically delayed; it may not
become noticeable until 24–48 hours later. |
|
Half-life |
15–58 hours (35 hours) [5,
6] |
Days to weeks; brodifacoum: 16–36 days above (
> 20 days), maybe longer [6]. |
|
Fat-soluble |
Moderate [7] |
Highly [8]. |
|
Tissue Accumulation |
Relatively limited |
Obviously, especially in the
liver, |
|
INR normalization |
Discontinuation of medication,
plus vitamin K if necessary, usually results in faster recovery. |
Even if INR temporarily returns
to normal, it may rise again. |
|
Vitamin K1 |
Usually, a low dose is
sufficient. |
High doses and long-term use
are often required. |
|
Time to observe |
Days to a week |
Weeks to months |
|
Outcome |
Proper treatment usually yields
good results. |
Timely treatment is usually
reversible, but delayed diagnosis can lead to severe bleeding or even death. |
| ||||||||||||||||||||||||||
References
[1]. https://pubmed.ncbi.nlm.nih.gov/41446851/
[2]. https://pubmed.ncbi.nlm.nih.gov/42497723/
[3]. https://pubmed.ncbi.nlm.nih.gov/29592891/
[4]. https://pubmed.ncbi.nlm.nih.gov/29659439/
[5]. https://pubmed.ncbi.nlm.nih.gov/3542339/
[6]. https://pmc.ncbi.nlm.nih.gov/articles/PMC4940222/
[7]. https://pubmed.ncbi.nlm.nih.gov/30949117/
[8]. https://pubmed.ncbi.nlm.nih.gov/17022046/
[9]. 急性中毒救命術. 急診醫學會三版p.338
[10]. https://www.ahajournals.org/doi/10.1161/circulationaha.111.081489
[11]. https://pmc.ncbi.nlm.nih.gov/articles/PMC4653986/
[12]. https://vimbook.vumc.org/hematology-oncology/anticoagulation
沒有留言:
張貼留言